60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
60 Degrees Pharmaceuticals's net income for the twelve months ending Jun 30, 2026 was -$8.11M. For fiscal 2025 it was -$7.37M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.37M | – |
| FY2024 | Dec 31, 2024 | -$7.95M | – |
| FY2023 | Dec 31, 2023 | -$3.77M | – |
| FY2022 | Dec 31, 2022 | -$6.18M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.26M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.44M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.88M | -535.9% |
| Q4 FY2024 | Dec 31, 2024 | -$2.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.16M | -151.6% |
| Q2 FY2024 | Jun 30, 2024 | -$4.17M | – |
| Q1 FY2024 | Mar 31, 2024 | $430.47K | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.01M | – |
| Q3 FY2023 | Sep 30, 2023 | $4.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.15M | – |